<DOC>
	<DOCNO>NCT00635778</DOCNO>
	<brief_summary>This study look high tolerate dose MK-0646 give every week infusion patient advance solid tumor .</brief_summary>
	<brief_title>Infusion MK-0646 Subjects With Advanced Solid Tumors ( MK-0646-002 ) ( COMPLETED )</brief_title>
	<detailed_description>Trial Duration Treatment : Patients receive study drug 12 week . Patients may able receive MK-0646 long 1 year seem stop growth cancer cause bad side effect . If patient complete response MK-0646 , may receive 8 additional week treatment .</detailed_description>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Males female advance solid tumor fail respond standard therapy , age 18 year old , adequate organ function Patient use growth hormone growth hormone inhibitor Patient know allergic component drug similar drug ( e.g . monoclonal antibody rituximab biological therapy immunoglobulin G Patient chemotherapy , radiotherapy , biological therapy within 4 6 week enter study recover previous therapy Patient take part take part study investigational compound device within 30 day first dose study drug Patient active Central Nervous System metastases and/or carcinomatous meningitis . However , patient complete course therapy clinically stable may able participate Patient pregnant breastfeeding Patient human immunodeficiency virus ( HIV ) positive Patient history Hepatitis B C Patient symptomatic ascites pleural effusion . However , patient receive treatment stable , may able participate Female patient plan become pregnant male patient plan impregnate partner time study go</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>